ADORA2A and cutaneous melanoma: In addition, skin melanoma patients expressing highly CD8, PDCD1, CD274, PDCD1LG2, CTLA-4, C10orf54 (VISTA), LAG3, HAVCR2, TIGIT, ILT2, ILT4, ADORA2A, IDO1 and IDO2 had better overall survival versus low-expressing patients.